










doi:10.101Thalidomide-Dexamethasone as Induction Therapy
before Autologous Stem Cell Transplantation
in Patients with Newly Diagnosed Multiple Myeloma
and Renal Insufficiency
Patrizia Tosi, Elena Zamagni, Paola Tacchetti, Michela Ceccolini, Giulia Perrone,
Annamaria Brioli, Maria Caterina Pallotti, Lucia Pantani, Alessandro Petrucci,
Michele Baccarani, Michele CavoThe aim of this study was to evaluate the efficacy and the toxicity of thalidomide-dexamethasone (Thal-Dex)
as induction therapy before autologous peripheral blood stem cell (PBSC) transplantation in patients with
newly diagnosed multiple myeloma (MM) with renal insufficiency. The study included 31 patients with a base-
line creatinine clearance value #50 mL/min, 7 of whom required chronic hemodialysis. Patients received 4
months of Thal-Dex, followed by PBSC collection and subsequent transplantation. After induction, a partial
response (PR) or greater was obtained in 23 patients (74%), including 8 (26%) who achieved a very good PR.
Renal function improved more frequently in patients achieving a PR or greater (82%, vs 37% in patients
achieving less than a PR; P 5 .04). Twenty-six patients underwent PBSC mobilization; in 17 of these patients
(65%), .4  106 CD341 cells/kg were collected. Double autologous transplantation was performed in 15
patients, and a single autologous transplantation was performed in 7 patients. After a median of 32 months of
follow-up, median event-free survival was 30 months, and median survival was not determined. According to
our data, Thal-Dex is effective and safe in patients with newly diagnosedMM and renal insufficiency. Given the
relationship between recovery of renal function and response to induction treatment, more intensive Thal1
bortezomib regimens could be explored to rescue higher numbers of patients.
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Renal insufficiency occurs in approximately 20%-
30% of patients with multiple myeloma (MM) at diag-
nosis and in .50% of patients with advanced disease
[1,2]. Several previous studies have pointed out that
despite their impaired renal function, a subset of
these patients can safely receive high-dose therapy
followed by autologous hematopoietic stem cell trans-
plantation (HSCT) and can achieve response rates
similar to those reported in patients with normal renalInstitute of Hematology and Medical Oncology ‘‘L. & A.
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6/j.bbmt.2010.02.020function [3-10]. Primary induction therapy is crucial,
because prompt reduction of tumor burden
combined with adequate supportive care can lead to
improved renal function in a significant percentage
of cases [11,12]. To achieve this important goal,
rapidly effective, nonnephrotoxic induction regimens
should be selected.
In most of the studies reported to date in patients
with newly diagnosed MM with renal insufficiency,
induction therapy involved either vincristine-
doxorubicin-dexamethasone (VAD), eventuallymodified
by replacing doxorubicin with another anthracycline,
or high-dose-dexamethasone [4,8,11,12]. In recent
years, many reports have drawn attention to the
efficacy of thalidomide-dexamethasone (Thal-Dex)
up-front in patients with newly diagnosed MM.
Specifically, Thal-Dex has demonstrated a superior
response rate compared with VAD in a case-matched
paired analysis [13] and compared with high-dose
dexamethasone in a multicentric randomized trial
[14]. Our group has previously reported that Thal-
Dex is active in patients with relapsed/refractory1115







Number of patients 15 16 31
Males/females 13/2* 5/11* 18/13
Median age, years (range) 60 (46-70) 60 (45-70) 60 (45-70)
Isotype, n
IgG 8 3 11
IgA 3 2 5
BJ 3** 10** 13
IgD 1 1 2
Light chain, n
K 10 8 18
L 5 8 13
D&S stage III, n 9 10 19
ISS stage III, n 9 8 17
*P 5 .006.
**P 5 .04.
1116 Biol Blood Marrow Transplant 16:1115-1121, 2010P. Tosi et al.MM with renal insufficiency [15], with an acceptable
toxicity profile. Pharmacokinetic studies have dem-
onstrated that the kidneys apparently are not in-
volved in Thal metabolism, because the drug
undergoes spontaneous hydrolysis in plasma, and
only a small amount is excreted unchanged in the
urine [16]. Furthermore, no correlation between
Thal clearance and renal function has been observed
[17]. Although 2 small studies have shown an unex-
plained incidence of hyperkalemia in MM patients
with renal insufficiency treated with Thal [18,19],
we did not observe this side effect in our larger
series of patients [15].
The aim of the present study was to investigate the
role of Thal-Dex as initial therapy for patients with
newly diagnosed MM and renal insufficiency who
were candidates for subsequent autologous HSCT.PATIENTS AND METHODS
Patients
Between May 2002 and February 2008, 31 consec-
utive patients (18 males, 13 females; median age, 60
years) with newly diagnosed MM and renal insuffi-
ciency provided informed consent to be enrolled in
a clinical trial of Thal-Dex up-front in preparation
for autologous HSCT. Baseline characteristics of the
entire patient population are reported in Table 1. Re-
nal insufficiency was defined as creatinine clearance
#50 mL/minute according to the Cockcroft-Gault
formula, confirmed by 2 different assays performed
at least 72 hours apart after appropriate hydration
therapy. Sixteen patients had a more severe renal
impairment, as defined by creatinine clearance \30
mL/min, and 7 of these patients required chronic
hemodialysis since diagnosis. Higher predominances
of female patients and of patients with the Bence-
Jones isotype were seen in the subgroup with a baseline
creatinine clearance\30 mL/min.Treatment Protocol
The study was an extension of the Bologna 2002
clinical trial [20]. According to the study design,
patients received 4 monthly courses of combined oral
Thal (100 mg/day for 2 weeks and 200 mg/day there-
after) and dexamethasone (40 mg/day on days 1-4, 9-
12, and 17-20 on odd cycles and on days 1-4 on even
cycles); fixed low-dose warfarin was administered as
prophylaxis for deep venous thrombosis [21]. Periph-
eral blood stem cell (PBSC) collection was performed
after priming with cyclophosphamide (Cy) 4 g/m2 and
granulocyte colony-stimulating factor (G-CSF) 5 mg/
kg/day. G-CSF alone was used in patients with creat-
inine clearance remaining at\30 mL/min after induc-
tion therapy. The minimum threshold dose of CD341cells collected in an attempt to safely perform a single
or a double ASCT was 2 or 4  106 per kg of body
weight, respectively. Autologous HSCT was subse-
quently carried out to support high-dose melphalan
(HD-Mel) at 200 or 140 mg/m2 depending on the cre-
atinine clearance value ($30 or\30 mL/min, respec-
tively). Three months later, a second transplantation
after preparation with HD-Mel was performed in pa-
tients with .4  106 CD341 cells/kg. Thal was ad-
ministered continuously throughout the induction
phase (4months), then withheld to allow priming ther-
apy with Cy 1 G-CSF or G-CSF alone. After PBSC
harvest, Thal administration was resumed, and it was
continued until completion of HSCT. The maximum
duration of Thal therapy for patients undergoing dou-
ble autologous HSCT was 8 months.
Renal function was monitored weekly during
induction therapy, twice weekly during the transplan-
tation procedure, and monthly thereafter.
Evaluation of Response
Criteria for defining a complete response (CR),
a very good partial response (VGPR), a partial response
(PR), or progressive disease (PD) were those reported
by the International Myeloma Study Group [22].
Evaluation of Toxicity
Adverse events (AEs) were assessed and graded ac-
cording to the National Cancer Institute’s Common
Toxicity Criteria, version 2.0.RESULTS
Response to Induction Treatment
On an intention-to-treat basis, at least a PR was
obtained in 23 patients (74%), including 3 (10%)
who achieved a CR and 5 (16%) who achieved








(n 5 16) Total (n 5 31)
PR, n (%) 11 (73%) 4 (25%) 15 (48%)
VGPR, n (%) 0 (0%) 5 (31%) 5 (16%)
CR, n (%) 2 (13%) 1 (6%) 3 (10%)
PR indicates partial response; VGPR, very good partial response; CR,
complete response.
Figure 1. Renal function before and after induction therapy in patients
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Renal Insufficiencya VGPR (Table 2). Of the remaining 8 patients, 2
achieved a minor response, 2 were treatment-
refractory, 2 exhibited disease progression, and 2
discontinued therapy after 1 month because of AE.
No significant difference in the response rate to
Thal-Dex, including VGPR or better response, was
observed between patients with a baseline creatinine
clearance .30 mL/min and those with a baseline
creatinine clearance #30 mL/min (87% and 13%
response rate vs 62.5% and 37.5%, respectively)
(Table 2). No treatment-related deaths were recorded.achieving (A) or not achieving (B) at least a PR.Renal Function
Recovery of normal renal function, defined as cre-
atinine clearance .50 mL/min, was observed in 17
patients (55%). Six patients (19%) demonstrated
improved creatinine clearance, with values ranging be-
tween 30 and 49 mL/min. In 9 patients, renal function
remained severely impaired (creatinine clearance\30
mL/min) (Table 3). Normal renal function was
achieved more frequently by patients with a lower
degree of renal insufficiency at baseline (93%, vs 19%
for those with creatinine clearance \30 mL/min;
P\.000). Consistent with these data is the observation
that all 9 patientswho failed to recover or improve renal
function hadmore severe renal impairment at baseline.
Furthermore, an increased creatinine clearance value
was significantly related to response to Thal-Dex: in
fact, of the 23 patients achieving at least a PR, 19
(82.6%) had improved renal function, with 15 (65%)
achieving a creatinine clearance value .50 mL/min.
The corresponding value in those patients who failed













14 (93%)* 3 (19%)* 17 (55%)
Creatinine clearance 30-50
mL/min, n (%)
1 (7%) 4 (25%) 5 (16%)
No improvement, n (%) 0 (0%) 9 (56%) 9 (29%)
*P <.00.(Figure 1B), with only 25% of these patients attaining
normal renal function. Two of 7 patients who were
dependent on chronic hemodialysis became dialysis-
independent; one patient who progressed on Thal-
Dex experienced rapidly deteriorating renal function
and underwent hemodialysis after 1 month of therapy.
AE
The toxic effects seen in this series of patients
during induction therapy were comparable to those
reported in patients with normal renal function [22].
Three patients (9.6%) developed deep venous throm-
bosis confirmed by Doppler ultrasonography; in one
of these patients, induction therapy was discontinued,
whereas the other 2 patients continued Thal while full
anticoagulation therapy with low molecular weight
heparin was instituted. Another patient discontinued
treatment after 1 month because of an extensive skin
rash, which resolved promptly after withdrawal of
Thal. Additional side effects included grade 1 periph-
eral neuropathy (3 patients), constipation (2 patients),
and lethargy (1 patient).
PBSC Mobilization and Collection
Five patients did not proceed to PBSC mobiliza-
tion because of poor performance status (2 patients)
or refractory/PD (3 patients, of whom 2 were subse-
quently salvaged with bortezomib-dexamethasone
therapy). Of the 26 remaining patients, 4 failed to col-
lect at least 2  106 CD341 cells/kg, 5 collected 2-4 
106 CD341 cells/kg and thus were scheduled for single











PBSC priming, n (%) 14 (93%) 12 (75%) 26 (84%)
Cyclophosphamide + G-CSF 14 (100%) 5 (42%) 19 (73%)
G-CSF alone 0 (0%) 7 (58%) 7 (27%)
PBSC collection, n (%) 14 (93%)* 8 (50%)* 22 (71%)
CD34+ cells 2-4  106/kg 2 (14%) 3 (37.5%) 5 (23%)
CD34+ cells >4  106/kg 12 (86%) 5 (62.5%) 17 (77%)
HSCT, n (%) 14 (93%) 8 (50%) 22 (71%)
Single 4 (29%) 3 (37.5%) 7 (32%)
Double 10 (71%) 5 (62.5%) 15 (68%)
PBSC indicates peripheral blood stem cell transplantation; G-CSF, gran-
ulocyte colony-stimulating factor; HSCT, hematopoietic stem cell trans-
plantation.
*P 5 .025.
Figure 2. EFS (dotted line) and OS (solid line) of patients enrolled in
the study. Data were analyzed on an intention-to-treat basis.
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tion) collected.4  106 CD341 cells/kg, sufficient to
support a double autologous HSCT (Table 4). PBSC
collection was accomplished in a significantly lower
percentage of patients presenting with greater impair-
ment of renal function at baseline (50% vs 93%; P 5
.02). This could be ascribed both to a lower percentage
of such patients proceeding to PBSC priming (75% vs
93%) and especially to a higher percentage of patients
undergoing priming with G-CSF alone. In fact, of the
7 patients treated with G-CSF alone, 4 failed to collect
at least 2 106 CD341 cells/kg, and 3 collected 2-4 
106 CD341 cells/kg; conversely; 89% of the patients
who were treated with Cy 1 G-CSF collected .4 
106 CD341 cells/kg. No grade 3-4 extrahematologic
toxicity was recorded in patients receiving cyclophos-
phamide 1 G-CSF as a PBSC priming regimen.Transplantation Procedure
and Transplantation-Related Toxicity
Of the 22 patients who successfully underwent
PBSC collection, 15 received a double HSCT and 7
received a single HSCT because of either inadequate
PBSC collection (5 patients) or delayed recovery of
a good performance status after a first HSCT (2
patients) (Table 4). All of the patients demonstrated
sustained engraftment, with 0.5 109 polymorphonu-
clear/liter and 20 109 platelets/liter after a median of
11 days and 13 days posttransplantation, respectively.
While neutropenic, 6 patients experienced grade 3
fever with no microbiological evidence of bacterial/
fungal infection. Grade III oral mucositis was observed
in 3 patients. No transplantation-related deaths were
recorded.Final Response and Survival
On an intention-to treat basis, a VGPR or better
was obtained in 13 patients (42%), 9 of whom (29%)achieved a CR. It is interesting to note that 11 of these
13 patients achieved normal renal function, compared
with 3 of 18 patients who failed to achieve a VGPR
(P 5 .00). The number of the patients enrolled in the
trial was probably too low to allow us to detect
a significant difference in response rate between pa-
tients receiving single HSCT (43% VGPR or better,
with 14% CR) and those receiving double HSCT
(66% VGPR or better, with 53% CR). At a median
of 32 months of follow-up, overall median event-free
survival (EFS) was 30 months, and median overall sur-
vival (OS) was not determined (Figure 2). Again,
because of the small number of patients, we failed to
observe a significant difference in median EFS (20
months vs 36 months) and OS (44 months vs not
reached) between patents undergoing single and dou-
ble autologous HSCT; nonetheless, EFS and OS
curves did not differ significantly between patients
with a baseline serum creatinine clearance of 30-50
mL/min and those with a baseline creatinine clearance
of\30 mL/min (Figure 3).
Figure 3. EFS (A) and OS (B) of patients presenting with a baseline cre-
atinine clearance of 30-50 mL/min and\30 mL/min.
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Renal InsufficiencyDISCUSSION
Thal-Dex has been demonstrated to be an effective
and feasible induction treatment for patients with
newly diagnosed MM [13,14]. In this present study,
we investigated this drug combination as up-front
therapy in a group of MM patients with renal insuffi-
ciency who were considered eligible for subsequent
autologous HSCT. The rate of at least PR to Thal-
Dex was comparable to that previously reported in
patients with normal renal function [22] and probably
superior to what can be achieved using other chemo-
therapeutic regimens [11,12], even though this
statement has not been supported by prospective
randomized trials. In addition, the rate of VGPR or
better (26%) was similar to that reported by our
group in the entire patient population enrolled in the
Bologna 2002 clinical trial [20,23]. The overall safety
profile of Thal-Dex in these patients is acceptable
and comparable to that seen in patients with normal
renal function.
A major problem that we faced when using this
drug combination in this subset of patients was thefeasibility of PBSC collection. Overall, only 58% of
the initial patient population succeeded in collecting
.4  106 CD341 cells/kg, even though 22 of the 31
patients (71%) who were actually submitted to PBSC
mobilization managed to collect at least 2  106
CD341 cells/kg. Although our data were obtained in
a small patient population, this percentage is inferior
to that reported with the use of Thal-based combina-
tions in patients with normal renal function. A possible
explanation for this finding could be that 7 patients (5
of whom failed to collect PBSCs) underwent priming
with G-CSF alone, which likely is less effective than
Cy 1 G-CSF in allowing more rapid stem cell collec-
tion and higher numbers of collected CD341 cells
[24]. Some previous reports have noted that previous
exposure to Thal might impair PBSC mobilization
[25] or at least reduce CD341 cell yields [26], although
not to an extent tomake it impossible to perform a dou-
ble autologous HSCT. Comparable results were seen
with long-tern lenalidomide administration before
PBSC collection without Cy priming in patients with
normal renal function [27].
But, despite these problems with PBSC mobiliza-
tion and collection (which need to be confirmed in
a larger series of patients), neither engraftment nor
toxicity was affected. After induction, 68% of the pa-
tients demonstrated improved renal function, with
55% achieving normal renal function. According to
our data, reversal of renal insufficiency appears to be
related to less-impaired renal function at the start of
treatment, and in line with the results reported by Kas-
tritis et al. [28] using either Thal or bortezomib in
combination with Dex. Response to therapy seems to
be a crucial factor in the reversal of renal insufficiency;
patients achieving at least a PR have a greater probabil-
ity of improving their renal function. Furthermore,
a better quality of response (VGPR or better) is related
to a higher probability of achieving a normal renal
function at the end of treatment. Bearing this in
mind, the treatment of patients with newly diagnosed
MM and renal insufficiency possibly could be im-
proved by increasing the speed and the rate of re-
sponse; the addition of bortezomib to the original
Thal-Dex combination could be explored for this pur-
pose. Preliminary results of a randomized clinical trial
of patients with newly diagnosed MM have demon-
strated that Thal-Dex-bortezomib is more effective
than Thal-Dex in terms of CR achievement [29], and
that this advantage is maintained after autologous
HSCT [30]. The possibility of worsening neuropathy
with the combination of Thal and bortezomib should
not be overlooked, however, even though preliminary
data show that the incidence of grade $3 peripheral
neuropathy does not exceed 9% [30]. Early studies
have demonstrated that in patients with MM and renal
failure, bortezomib-containing regimens are effective
in terms of both reduction of tumor burden and
1120 Biol Blood Marrow Transplant 16:1115-1121, 2010P. Tosi et al.improvement of renal function [31,32]. Analyses of
data from a large randomized trial conducted in
patients with newly diagnosed MM [33,34] show that
response rate and toxicity in the bortezomib-
melphalan-prednisone arm (VMP) was not affected
by renal failure; moreover, compared with the
melphalan-prednisone arm, treatment with VMP re-
sulted in a higher percentage of patients achieving nor-
mal renal function in a shorter period of time. Several
studies [34-36] have pointed out that the reversal of
renal failure after bortezomib-containing regimens is
related to the response to therapy, and also that these
regimens warrant rapid responses, whichmight be cru-
cial to increasing the likelihood of reversing renal in-
sufficiency. Bortezomib seems to act specifically on
the pathogenesis of myeloma-related renal insuffi-
ciency. Inhibition of nuclear factor kappa light-chain
enhancer of activated B cells could potentially prevent
the cytokine-mediated inflammatory damage to the
kidney interstitium seen in MM [37-39], as well as
the mesangial alterations that can be detected in
light-chain deposition disease [40,41]. These findings,
together with our data, suggest that Thal-bortezomib
combination therapy might be useful as initial therapy
in patients with MM and renal insufficiency.ACKNOWLEDGMENTS
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